|本期目录/Table of Contents|

[1]李 奇,张 凯,思兰兰,等.隐匿性HBV 感染患者HBV S 基因突变特点及突变病毒株致瘤性研究[J].传染病信息,2019,03:208-214.
 LI Qi,ZHANG Kai,SI Lan-lan,et al.Study on the characteristics of HBV S gene mutation and thetumorigenicity of mutant virus strain in patients with occult HBV infection[J].Infectious Disease Information,2019,03:208-214.
点击复制

隐匿性HBV 感染患者HBV S 基因突变特点及突变病毒株致瘤性研究(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2019年03期
页码:
208-214
栏目:
论 著
出版日期:
2019-07-12

文章信息/Info

Title:
Study on the characteristics of HBV S gene mutation and thetumorigenicity of mutant virus strain in patients with occult HBV infection
文章编号:
   1007-8134(2019)03-0208-07
作者:
李 奇张 凯思兰兰陈建宏刘桃园纪 冬李晓东刘 妍徐东平
541004,桂林医学院基础医学院(李奇、徐东平);100039北京,中国人民解放军总医院第五医学中心临床研究管理中心(张凯、思兰兰、陈建宏、刘桃园、李晓东、刘妍、徐东平)
Author(s):
LI Qi ZHANG Kai SI Lan-lan CHEN Jian-hong LIU Tao-yuan JI Dong LI Xiao-dong LIU Yan* XU Dong-ping*
College of Basic Medicine, Guilin Medical University, 541004, China
关键词:
乙型肝炎病毒隐匿性感染主要亲水区突变致瘤性
Keywords:
hepatitis B virus occult infection major hydrophilic region mutation tumorigenicity
分类号:
R512.6    
DOI:
10.3969/j.issn.1007-8134.2019.03.004
文献标识码:
A
摘要:
目的 研究肝病人群中隐匿性 HBV感染( occult hepatitis B virus infection, OBI)患者 HBV S基因主要亲水区(major hydrophilic region, MHR)的突变特点及突变病毒株的致瘤性。方法 回顾性分析 2011年 9月—2016年 3月中国人民解放军总医院第五医学中心血清库中收集的 10 359例样本及其患者临床资料,分析 OBI检出率及其 HBV S基因 MHR突变特点。通过细胞增殖、平板克隆、细胞划痕、细胞小室迁移和细胞周期等实验方法,分析 1株典型的新型突变病毒株的致瘤性。结果 筛查出血清 HBsAg阴性及 HBV DNA阳性的 OBI患者 14例,OBI检出率为 0.191%(14/7323)。14例患者中检出 9种 MHR突变类型,其中新发现 126-127“RPCMNCTI”插入和 F161S 2种突变。细胞肿瘤表型实验结果显示,与空载体对照组和野生组细胞相比,突变组细胞的增殖、克隆形成和迁移能力均明显增加( P均< 0.05)。结论 本研究显示肝病人群中有较高的 OBI检出率,且多数患者可检出文献报道的 OBI相关突变。 HBV S基因 126-127“RPCMNCTI”插入新型突变具有促进肿瘤生长的细胞生物学特点,可能会增加慢性 HBV感染患者向肝癌进展的潜在风险。  
Abstract:
Objective To study the mutation characteristics of the major hydrophilic region (MHR) of HBV S gene and thetumorigenicity of the mutant virus strain in patients with occult hepatitis B virus infection (OBI). Methods A retrospective study was performed on 10 359 patient samples selected from our hospital serum bank from September 2011 to March 2016, The detection rateof OBI and the characteristics of the HBV S gene MHR mutation were analyzed. The tumorigenicity of a new and representative mutantvirus strain was analyzed through cell proliferation assay, colony formation, scratch assay, transwell and cell cycle assay. Results Fourteen OBI patients with negative serum HBsAg and positive HBV DNA were screened, and the OBI detection ratewas 0.191% (14/7323). Among the 14 patients, 9 MHR mutations were detected, including 2 new mutations, 126-127 “RPCMNCTI” insertion and F161S. The results of cell tumor phenotype experiments showed that the abilities of cell proliferation, clone formation and migration in the mutant group were significantly increased, compared with the blank-vector control group and the wild-type group (P< 0.05). Conclusions In this study, the OBI detection rate is relatively high in the liver disease population, and literatury-reported-OBI related mutations can be detected in most OBI patients. The new mutant virus strain (126-127 “RPCMNCTI” insertion) of HBV S gene has biological characteristics of promoting tumor growth, which may increase the potential risk of progression to liver cancer in patients with chronic HBV infection.      

参考文献/References


[1] Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection[J]. J Hepatol, 2008, 49(4):652-657.
[2] 张涛,廖红梅,张春红,等 . 重庆地区无偿献血人群隐匿
性乙型肝炎病毒感染的特征[J]. 传染病信息,2017, 30(1):44-47.
[3] Wang Z, Zeng J, Li T, et al. Prevalence of hepatitis B surfaceantigen (HBsAg) in a blood donor population born prior to and afterimplementation of universal HBV vaccination in Shenzhen, China
[J]. BMC Infect Dis, 2016, 16(1):498.
[4] Kiely P, Margaritis AR, Seed CR, et al. Hepatitis B virus nucleicacid amplification testing of Australian blood donors highlights the complexity of confirming occult hepatitis B virus infection[J]. Transfusion, 2014, 54(8):2084-2091.
[5] Chen BF. Hepatitis B virus Pre-S/S variants in liver diseases[J]. World J Gastroenterol, 2018, 24(14):1507-1520.
[6] Coppola N, Onorato L, Iodice V, et al. Occult HBV infection in HCC and cirrhotic tissue of HBsAg-negative patients: a virological and clinical study[J]. Oncotarget, 2016, 7(38):62706-62714.
[7] Levrero M, Zucman-Rossi J. Mechanisms of HBV-inducedhepatocellular carcinoma[J]. J Hepatol, 2016, 64(1 Suppl):S84-S101.
[8] 粘学渊,许智慧,刘妍,等 . HBV基因突变与肝细胞癌发生关系研究进展[J]. 传染病信息,2015,28(5):306-309.
[9] 陈建宏,刘妍,许智慧,等 . 隐匿性乙型肝炎病毒感染患者 S基因突变特点分析[J]. 解放军医学杂志,2015,40(3):178-
183.
[10] Chen J, Liu Y, Zhao J, et al. Characterization of novel hepatitis Bvirus PreS/S-gene mutations in a patient with occult hepatitis Bvirus infection[J]. PLoS One, 2016, 11(5):e0155654.
[11] Lin H, Zhao H, Tang X, et al. Serological patterns and molecularcharacterization of occult hepatitis B virusv infection among blood
donors[J]. Hepat Mon, 2016, 16(10):e40492.
[12] Lambert C, Prange R. Posttranslational N-glycosylation of thehepatitis B virus large envelope protein[J]. Virol J, 2007, 4:45.
[13] Salpini R, Colagrossi L, Bellocchi MC, et al. Hepatitis B surfaceantigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression[J]. Hepatology, 2015, 61(3):823-833.
[14] Pollicino T, Cacciola I, Saffioti F, et al. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications[J].J Hepatol, 2014, 61(2):408-417.
[15] Choi YM, Lee SY, Kim BJ. Naturally occurring hepatitis B virusmutations leading to endoplasmic reticulum stress and theircontribution to the progression of hepatocellular carcinoma[J]. Int J Mol Sci, 2019, 20(3):597.
[16] 刘妍,张凯,陈容娟,等 . 隐匿性 HBV感染患者 HBV S基因 N-糖基化突变对HBsAg抗原性影响的分析[J]. 解放军医学杂志, 2018,43(5):386-391.
[17] Zhang K, Liu Y, Chen R, et al. Antigenicity reduction contributesmostly to poor detectability of HBsAg by hepatitis B virus (HBV)S-gene mutants isolated from individuals with occult HBV infection
[J]. J Med Virol, 2018, 90(2):263-270.
[18] 乔艳,许智慧,卢姗姗,等 . HBsAg和抗 HBs双阳性慢性 HBV感染患者 S区主要亲水区新增 N-糖基化突变与肝细胞癌发生风险的相关性研究[J]. 解放军医学杂志,2016, 41(11):919-924.

备注/Memo

备注/Memo:
[基金项目 ] 国家自然科学基金(81572010);北京市自然科学基金(7172206);首都卫生发展科研专项(2016-2-5032)[作者单位] 541004,桂林医学院基础医学院(李奇、徐东平);100039北京,中国人民解放军总医院第五医学中心临床研究管理中心(张凯、思兰兰、陈建宏、刘桃园、李晓东、刘妍、徐东平)
[通信作者] 刘妍,E-mail: liuyan5360@163.com;徐东平,E-mail: xudongping302@sina.com
更新日期/Last Update: 2019-07-12